scholarly journals Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer

2019 ◽  
Vol 15 (25) ◽  
pp. 2943-2953 ◽  
Author(s):  
Kellie J Ryan ◽  
Karen E Skinner ◽  
Ancilla W Fernandes ◽  
Rajeshwari S Punekar ◽  
Melissa Pavilack ◽  
...  
Keyword(s):  
Real World ◽  
Medical Records ◽  
Unmet Needs ◽  
Treatment Patterns ◽  
Stage Iii ◽  
National Guidelines ◽  
Community Oncology ◽  
Recent Treatment ◽  
Stage Iii Nsclc ◽  
Platinum Chemotherapy

Aim: Little is known about recent treatment patterns among patients with unresected stage III NSCLC in the real world. This retrospective study used medical records from USA community oncology practices to address this knowledge gap. Materials & methods: Eligible patients were stage III NSCLC adults diagnosed between 1 January 2011 and 1 March 2016 without surgical resection. Treatment patterns were assessed across three progression intervals, from stage III diagnosis through third progression. Results: The most common regimen in interval 1 was platinum doublet chemotherapy + radiation therapy, in interval 2 was chemotherapy only, and in interval 3 was non-platinum chemotherapy monotherapy. Conclusion: Most patients were treated following national guidelines, but important unmet needs remain.

scholarly journals Treatment patterns and clinical outcomes with palbociclib-based therapy received in US community oncology practices

2020 ◽  
Author(s):  
Junji Lin ◽  
Lynn McRoy ◽  
Maxine D Fisher ◽  
Nan Hu ◽  
Cralen Davis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcomes ◽  
Real World ◽  
Medical Records ◽  
Metastatic Breast ◽  
Patient Characteristics ◽  
Treatment Patterns ◽  
Community Oncology ◽  
Label Indication ◽  
Free Rate

Background: Limited studies have evaluated palbociclib-based therapy use in patients with advanced/metastatic breast cancer in the real world. This retrospective study used medical records from US community oncology practices to address the gap. Materials & methods: Eligible patients receiving palbociclib-based therapy per label indication from 3 February 2015 to 31 December 2017 were included. Descriptive analyses were conducted for patient characteristics, treatment patterns and clinical outcomes. Results: The study included 233 patients who received palbociclib + aromatase inhibitor (P+AI) and 48 who received palbociclib + fulvestrant (P+F). Real-world progression-free rate for P+AI was 69.8% (46.8%) at 12 (24) months (P+F: 43.5% [39.9%]) months. Real-world survival rate was 89.8% (71.4%) at 12 (24) months (P+F: 76.3% [65.0%]). Conclusion: The study findings are consistent with previous studies of palbociclib-based therapy.

scholarly journals P08.07 Clinical Characteristics and Treatment Patterns of NSCLC Stage III Patients from Real World

2021 ◽  
Vol 16 (3) ◽  
pp. S284
Author(s):  
L. Kathmann ◽  
J. Roeper ◽  
K. Wedeken ◽  
K. Willborn ◽  
F. Griesinger
Keyword(s):  
Real World ◽  
Clinical Characteristics ◽  
Treatment Patterns ◽  
Stage Iii

scholarly journals Real-World Treatment of Stage III NSCLC: The Role of Trimodality Treatment in the Era of Immunotherapy

2019 ◽  
Vol 14 (8) ◽  
pp. 1430-1439 ◽  
Author(s):  
Sara Moore ◽  
Bonnie Leung ◽  
Jonn Wu ◽  
Cheryl Ho
Keyword(s):  
Real World ◽  
Stage Iii ◽  
Stage Iii Nsclc ◽  
Trimodality Treatment

scholarly journals 1247P Uptake of durvalumab in the management of stage III NSCLC: The real-world application of PACIFIC

2020 ◽  
Vol 31 ◽  
pp. S807-S808
Author(s):  
S. Kuang ◽  
M. Liu ◽  
C. Ho ◽  
E. Berthelet ◽  
J. Laskin ◽  
...  
Keyword(s):  
Real World ◽  
Stage Iii ◽  
The Real ◽  
Real World Application ◽  
Stage Iii Nsclc
Sign in / Sign up

Export Citation Format

Share Document